Research Progress on Challenges in In Vivo CAR-T Cell Therapy
DOI:
https://doi.org/10.54097/45qbqc61Keywords:
CAR-T Cell Therapy, Approved Gene Therapy, In Vivo CAR-T Cells, Gene DeliveryAbstract
The emergence of chimeric antigen receptor (CAR) T-cell therapy heralds a paradigm shift in cancer immunotherapy. Different from in-vitro CAR-T products, in-vivo CAR-T engineering accomplishes in-situ reprogramming of endogenous T cells, making possible long-lasting anti-tumor cytotoxic activity, which is cost-effective in production and has immediate accessibility as an off-the-shelf product. However, challenges like low target specificity, immune suppression in the tumor microenvironment, treatment resistance, and safety concerns do impede its clinical translational application. This review summarizes the main CAR delivery vectors representative preclinical and clinical studies as well as new strategies to overcome current limitations with the purpose of facilitating the clinical development of this emerging therapy.
Downloads
References
[1] Nicolai, C. J., Parker, M. H., Qin, J., Tang, W., Ulrich-Lewis, J. T., Gottschalk, R. J., Cooper, S. E., Hernandez Lopez, S. A., Parrilla, D., Mangio, R. S., Ericson, N. G., Brandes, A. H., Umuhoza, S., Michels, K. R., McDonnell, M. M., Park, L. Y., Shin, S., Leung, W. H., Scharenberg, A. M., Kiem, H. P., Larson, R. P., Beitz, L. O., & Ryu, B. Y. (2024). In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood, 144(9), 977–987. https://doi.org/10.1182/blood.2024024523. DOI: https://doi.org/10.1182/blood.2024024523
[2] López, A., Charbonnier, D., Vela, P., Díez, B., Río, P., Sánchez, R., Alberquilla, O., Martín-Antonio, B., Minguillón, J., Esquinas, E., García-Escudero, R., Errazquin, R., Del Marro, S., Pascual, A., Lorz, C., Juarranz, Á., Barahona, A., Balmaña, J., Maher, J., Bueren, J. A., & Casado, J. A. (2025). Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia. Molecular Therapy – Oncology, 33(4), 201060. https://doi.org/10.1016/j.omton.2025.201060. DOI: https://doi.org/10.1016/j.omton.2025.201060
[3] Jadlowsky, J. K., Hexner, E. O., Marshall, A., Grupp, S. A., Frey, N. V., Riley, J. L., Veloso, E., McConville, H., Rogal, W., Czuczman, C., Hwang, W. T., Li, Y., Leskowitz, R. M., Farrelly, O., Karar, J., Christensen, S., Barber-Rotenberg, J., Gaymon, A., Aronson, N., Bernstein, W., Melenhorst, J. J., Roche, A. M., Everett, J. K., Zolnoski, S. A., McFarland, A. G., Reddy, S., Petrichenko, A., Cook, E. J., Lee, C., Gonzalez, V. E., Alexander, K., Kulikovskaya, I., Ramírez-Fernández, Á., Minehart, J. C., Ruella, M., Gill, S. I., Schuster, S. J., Cohen, A. D., Garfall, A. L., Shah, P. D., Porter, D. L., Maude, S. L., Levine, B. L., Siegel, D. L., Chew, A., McKenna, S., Lledo, L., Davis, M. M., Plesa, G., Herbst, F., Stadtmauer, E. A., Tebas, P., DiNofia, A., Haas, A., Haas, N. B., Myers, R., O'Rourke, D. M., Svoboda, J., Tanyi, J. L., Aplenc, R., Jacobson, J. M., Ko, A. H., Cohen, R. B., June, C. H., Bushman, F. D., & Fraietta, J. A. (2025). Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nature Medicine, 31(4), 1134–1144. https://doi.org/10.1038/s41591-024-03478-6. DOI: https://doi.org/10.1038/s41591-024-03478-6
[4] Naso, M. F., Tomkowicz, B., Perry, W. L., 3rd, & Strohl, W. R. (2017). Adeno-Associated Virus (AAV) as a vector for gene therapy. BioDrugs, 31(4), 317–334. https://doi.org/10.1007/s40259-017-0234-5. DOI: https://doi.org/10.1007/s40259-017-0234-5
[5] Borrás, T., Xue, W., Choi, V. W., Bartlett, J. S., Li, G., Samulski, R. J., & Chisolm, S. S. (2006). Mechanisms of AAV transduction in glaucoma-associated human trabecular meshwork cells. The Journal of Gene Medicine, 8(5), 589–602. https://doi.org/10.1002/jgm.886. DOI: https://doi.org/10.1002/jgm.886
[6] Lech, P., & Somia, N. V. (2008). Retrovirus vectors. Contributions to Nephrology, 159, 30–46. https://doi.org/10.1159/000125574. DOI: https://doi.org/10.1159/000125574
[7] Date, T., Nimbalkar, V., Kamat, J., Mittal, A., Mahato, R. I., & Chitkara, D. (2018). Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics. Journal of Controlled Release, 271, 60–73. https://doi.org/10.1016/j.jconrel.2017.12.016. DOI: https://doi.org/10.1016/j.jconrel.2017.12.016
[8] Bordat, A., Boissenot, T., Nicolas, J., & Tsapis, N. (2019). Thermoresponsive polymer nanocarriers for biomedical applications. Advanced Drug Delivery Reviews, 138, 167–192. https://doi.org/10.1016/j.addr.2018.10.005. DOI: https://doi.org/10.1016/j.addr.2018.10.005
[9] Guerassimoff, L., Ferrere, M., Bossion, A., & Nicolas, J. (2024). Stimuli-sensitive polymer prodrug nanocarriers by reversible-deactivation radical polymerization. Chemical Society Reviews, 53(12), 6511–6567. https://doi.org/10.1039/d2cs01060g. DOI: https://doi.org/10.1039/D2CS01060G
[10] Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2022). Chemistry of lipid nanoparticles for RNA delivery. Accounts of Chemical Research, 55(1), 2–12. https://doi.org/10.1021/acs.accounts.1c00544. DOI: https://doi.org/10.1021/acs.accounts.1c00544
[11] Ibrahim, S. A., & Khan, Y. S. (2023). Histology, extracellular vesicles. In StatPearls. StatPearls Publishing.
[12] Michels, A., Frank, A. M., Günther, D. M., Mataei, M., Börner, K., Grimm, D., Hartmann, J., & Buchholz, C. J. (2021). Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8. Molecular Therapy – Methods & Clinical Development, 23, 334–347. https://doi.org/10.1016/j.omtm.2021.09.014. DOI: https://doi.org/10.1016/j.omtm.2021.09.014
[13] Dai, X., Park, J. J., Du, Y., Na, Z., Lam, S. Z., Chow, R. D., Renauer, P. A., Gu, J., Xin, S., Chu, Z., Liao, C., Clark, P., Zhao, H., Slavoff, S., & Chen, S. (2023). Massively parallel knock-in engineering of human T cells. Nature Biotechnology, 41(9), 1239–1255. https://doi.org/10.1038/s41587-022-01639-x. DOI: https://doi.org/10.1038/s41587-022-01639-x
[14] Meng, X., Fu, K., Liu, Y., Liu, Y., Zhang, J. Z., Kang, X., Wu, C., & Tsai, Y. H. (2026). Disulfide-directed multicyclic peptides for chimeric antigen receptors targeting solid tumors. Journal of the American Chemical Society, 148(1), 400–413. https://doi.org/10.1021/jacs.5c13642. DOI: https://doi.org/10.1021/jacs.5c13642
[15] Kondo, T., Bourassa, F. X. P., Achar, S., DuSold, J., Céspedes, P. F., Ando, M., Dwivedi, A., Moraly, J., Chien, C., Majdoul, S., Kenet, A. L., Wahlsten, M., Kvalvaag, A., Jenkins, E., Kim, S. P., Ade, C. M., Yu, Z., Gaud, G., Davila, M., Love, P., Yang, J. C., Dustin, M. L., Altan-Bonnet, G., François, P., Taylor, N. (2025). Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. Cell, 188(9), 2372–2389.e35. https://doi.org/10.1016/j.cell.2025.03.017. DOI: https://doi.org/10.1016/j.cell.2025.03.017
[16] Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020). Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Letters, 20(3), 1578–1589. https://doi.org/10.1021/acs.nanolett.9b04246. DOI: https://doi.org/10.1021/acs.nanolett.9b04246
[17] Zhang, Z., Ma, B., Li, B., Li, Z., Gao, M., Zhao, H., Peng, R., Hu, J., Wang, Y., You, W., Gui, X., Wang, R., Hu, X., Chen, B., Zhang, Y., Hao, Y., Sun, X., Rao, P., Zhang, L., Lu, M., Zhou, D., Yang, Y., Deng, M., & Miao, L. (2025). Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Reports Medicine, 6(7), 102209. https://doi.org/10.1016/j.xcrm.2025.102209. DOI: https://doi.org/10.1016/j.xcrm.2025.102209
[18] Bimbo, J. F., van Diest, E., Murphy, D. E., Ashoti, A., Evers, M. J. W., Narayanavari, S. A., Vaz, D. P., Rijssemus, H., Zotou, C., Saber, N., Lei, Z., Mayrhofer, P., Geerlings, M., Schiffelers, R., & Lubelski, J. (2025). T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. Journal for Immunotherapy of Cancer, 13(7), e011759. https://doi.org/10.1136/jitc-2025-011759. DOI: https://doi.org/10.1136/jitc-2025-011759
[19] Zhu, T., Chen, Z., Jiang, G., & Huang, X. (2023). Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy. ACS Nano, 17(17), 16770–16786. https://doi.org/10.1021/acsnano.3c03456. DOI: https://doi.org/10.1021/acsnano.3c03456
[20] Baldacci, S., Brea, E. J., Facchinetti, F., Li, Z., Ngo, K., Malhotra, S., Booker, M. A., Tolstorukov, M. Y., Chakravarti, S., Hinchey, C., Mahadevan, N. R., Lococo, F., D'Agnelli, S., Gnetti, L., Campanini, N., Leonetti, A., Feng, W. W., Tsai, J. A., Hartley, A. V., Locquet, M. A., Fournel, L., Alifano, M., Mansuet-Lupo, A., Saldanha, A., Haller, W., Zasadil, L. M., Zielinska, M., Bui, K., Tuladhar, B., Lizotte, P. H., Ivanova, E. V., Sequist, L. V., Gokhale, P. C., Paweletz, C. P., Smith, E. L., Jänne, P. A., & Barbie, D. A. (2025). Eradicating drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy. Cancer Discovery, 15(11), 2235–2250. https://doi.org/10.1158/2159-8290.CD-24-1515. DOI: https://doi.org/10.1158/2159-8290.CD-24-1515
[21] Zhong, W., Xiao, Z., Qin, Z., Yang, J., Wen, Y., Yu, Z., Li, Y., Sheppard, N. C., Fuchs, S. Y., Xu, X., Herlyn, M., June, C. H., Puré, E., & Guo, W. (2023). Tumor-derived small extracellular vesicles inhibit the efficacy of CAR T cells against solid tumors. Cancer Research, 83(16), 2790–2806. https://doi.org/10.1158/0008-5472.CAN-22-2220. DOI: https://doi.org/10.1158/0008-5472.CAN-22-2220
[22] Zhai, Y., Du, Y., Li, G., Yu, M., Hu, H., Pan, C., Wang, D., Shi, Z., Yan, X., Li, X., Jiang, T., & Zhang, W. (2023). Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. Signal Transduction and Targeted Therapy, 8(1), 457. https://doi.org/10.1038/s41392-023-01708-w. DOI: https://doi.org/10.1038/s41392-023-01708-w
[23] Fan, M., Liu, H., Yan, H., Che, R., Jin, Y., Yang, X., Zhou, X., Yang, H., Ge, K., Liang, X. J., Zhang, J., & Li, Z. (2022). A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy. Biomaterials, 282, 121424. https://doi.org/10.1016/j.biomaterials.2022.121424. DOI: https://doi.org/10.1016/j.biomaterials.2022.121424
[24] Hirabayashi, K., Du, H., Xu, Y., Shou, P., Zhou, X., Fucá, G., Landoni, E., Sun, C., Chen, Y., Savoldo, B., & Dotti, G. (2021). Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nature Cancer, 2(9), 904–918. https://doi.org/10.1038/s43018-021-00244-2. DOI: https://doi.org/10.1038/s43018-021-00244-2
[25] Tian, Y., Zhang, L., Ping, Y., Zhang, Z., Yao, C., Shen, C., Li, F., Wen, C., & Zhang, Y. (2025). CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. Cancer Immunology, Immunotherapy, 74(2), 55. https://doi.org/10.1007/s00262-024-03909-w. DOI: https://doi.org/10.1007/s00262-024-03909-w
[26] Pang, Y., Chen, L., Sun, Q., He, N., Lai, Z., Wang, X., Xie, Z., Yang, W., & Wang, W. (2025). A new strategy for CAR-T therapy in solid tumors: IL-15-autocrine signaling augments tumor stroma depletion and promotes a TSCM subset in the TME. Cell Death & Disease, 17(1), 39. https://doi.org/10.1038/s41419-025-08405-2. DOI: https://doi.org/10.1038/s41419-025-08405-2
[27] Niu, C., Wei, H., Pan, X., Wang, Y., Song, H., Li, C., Qie, J., Qian, J., Mo, S., Zheng, W., Zhuma, K., Lv, Z., Gao, Y., Zhang, D., Yang, H., Liu, R., Wang, L., Tu, W., Liu, J., Chu, Y., & Luo, F. (2025). Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell Metabolism, 37(6), 1426–1441.e7. https://doi.org/10.1016/j.cmet.2025.04.008. DOI: https://doi.org/10.1016/j.cmet.2025.04.008
[28] Wu, Y., Huang, Z., Liu, Y., He, P., Wang, Y., Yan, L., Wang, X., Gao, S., Zhou, X., Yoon, C. W., Sun, K., Situ, Y., Ho, P., Zeng, Y., Yuan, Z., Zhu, L., Zhou, Q., Zhao, Y., Liu, T., Kwong, G. A., Chien, S., Liu, L., & Wang, Y. (2024). Ultrasound control of genomic regulatory toolboxes for cancer immunotherapy. Nature Communications, 15(1), 10444. https://doi.org/10.1038/s41467-024-54477-7. DOI: https://doi.org/10.1038/s41467-024-54477-7
[29] Nyberg, W. A., Bernard, P. L., Ngo, W., Wang, C. H., Ark, J., Rothrock, A., Borgo, G. M., Kimmerly, G. R., Jung, J. H., Allain, V., Hamilton, J. R., Baldwin, A., Stickels, R., Wyman, S., Khan, S. H., Lang, S., Marsh, D., Almudhfar, N., Novick, C., Mortazavi, Y., Zhang, S., AbdElwakil, M. M., Sandoval, L. R., Hwang, S., Chu, S. N., Jung, H., Liu, C., Sharma, D., McCreary, T., Li, Z., Satpathy, A. T., Carnevale, J., Rutishauser, R. L., Cromer, M. K., Roybal, K. T., Dodgson, S. E., Doudna, J. A., Asokan, A., & Eyquem, J. (2026). In vivo site-specific engineering to reprogram T cells. Nature, 652(8110), 712–721. https://doi.org/10.1038/s41586-026-10235-x. DOI: https://doi.org/10.1038/s41586-026-10235-x
[30] Gong, N., Han, X., Xue, L., El-Mayta, R., Metzloff, A. E., Billingsley, M. M., Hamilton, A. G., & Mitchell, M. J. (2023). In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity. Nature Materials, 22(12), 1571–1580. https://doi.org/10.1038/s41563-023-01646-6. DOI: https://doi.org/10.1038/s41563-023-01646-6
[31] Li, H. M., Wang, Z. C., Huang, L., et al. (2025). Suppression of cytokine release syndrome by conjugating TCR signaling-responsive siltuximab nanogels with CAR-T cells. Nano Research, 18, 94908075. https://doi.org/10.26599/NR.2025.94908075. DOI: https://doi.org/10.26599/NR.2025.94908075
[32] Nguyen, N. T., Huang, K., Zeng, H., Jing, J., Wang, R., Fang, S., Chen, J., Liu, X., Huang, Z., You, M. J., Rao, A., Huang, Y., Han, G., & Zhou, Y. (2021). Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nature Nanotechnology, 16(12), 1424–1434. https://doi.org/10.1038/s41565-021-00982-5. DOI: https://doi.org/10.1038/s41565-021-00982-5
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
